

Editor-in-Chief:
S.J. Enna University of Kansas, USA

Editors: J.G. Piette University of Liège, Belgium
G.Z. Feuerstein Wyeth Research, USA
Commentary Editor: M. Williams Cephalon, Inc., USA

Biochemical Pharmacology Editorial Office:
University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 4016, Kansas City,
Kansas 66160, USA, Tel: +1-913-588-7533, Fax: +1-913-588-7373, Email: BP@kumc.edu

EDITORIAL ADVISORY BOARD:

Antibiotics & Chemotherapeutics

B.B. Aggarwal	University of Texas M.D. Anderson Cancer Center, USA
C. Bailly	Institut de Recherche Pierre Fabre, France
S. Ceruti	University of Milano, Italy
B.S. Cummings	University of Georgia, USA
E. De Clercq	Catholic University of Leuven, Belgium
M. Diederich	Cancer and Blood Disease Research Foundation, Luxembourg
J.D. Docquier	University of Siena, Italy
C. Elferink	University of Texas Medical Branch, USA
F.A.E. Kruyt	University Medical Center Groningen, The Netherlands
H.P. Gerber	Wyeth Research, USA
D.A. Gewirtz	Virginia Commonwealth University Massey Cancer Center, USA
O. Handa	Kyoto Prefectural University of Medicine, Japan
B.A. Ruggeri	Cephalon, Inc., USA
G.L. Russo	National Research Council, Italy
C. Michiels	University of Namur, Belgium
S. S. Singhal	University of North Texas Health Science Center, USA
K. Smalley	Moffitt Cancer Center, USA
B.A. Teicher	Genzyme Corporation, USA
K.D. Tew	Medical University of South Carolina, USA
F. Zunino	National Institute for the Study and Cure of Tumors, Italy

Cardiovascular

J.J. Badimon	Mount Sinai School of Medicine, USA
M.R. Bennett	University of Cambridge, UK
Y-H. Feng	Uniformed Services University of the Health Sciences, USA
B. M. Frey-von Matt	University of Bern, Switzerland
R.A. Khalil	Harvard Medical School, USA
D. Miller	Wyeth Research, USA
D. Newby	University of Edinburgh, UK
E.H. Ohlstein	Venuvics Pharmaceuticals, USA
R.G. Schaub	Archemix Corporation, USA
A.M. Schmidt	Columbia University Medical Center, New York, USA
B. Staels	University of Lille II, France
J. Winaver	Technion, IIT, Israel
R.J. Winquist	Vertex Pharmaceuticals, USA

Metabolic Disorders and Endocrinology

N. Chattopadhyay	Central Drug Research Institute, India
J.R. Colca	Kalamazoo Metabolic Research, USA
A. Kowluru	Wayne State University, USA
J. Pierre	INSERM U93-01, France
M.E. Poirot	INSERM U563, France
C.D. Sutherland	University of Dundee, UK

Inflammation & Immunopharmacology

M.J. Alcaraz	University of Valencia, Spain
G.F. Babcock	University of Cincinnati Medical Center, USA
R. Beyaert	University of Gent, Belgium
A. Bowie	Trinity College, Ireland
F. D'Acquisto	William Harvey Research Institute, UK
J. El Benna	Université Paris (INSERM), France
M.P. Fink	Logical Therapeutics, USA
K.B. Glaser	Abbott Laboratories, USA
O. Léo	Université Libre de Bruxelles, Belgium
J.-H. Lai	National Defense Medical Center, Taiwan, ROC
J.J. Moreno	University of Barcelona, Spain
M. Mousli	University of Strasbourg, France
D. R. Webb	Celgene Research, USA

Neuropharmacology

J. Bergman	Harvard Medical School, USA
D.C. Bertrand	University of Geneva, Switzerland
R.A.J. Challiss	University of Leicester, UK
C. Forray	Lundbeck Research USA
E.D. Hall	University of Kentucky Medical Center, USA
M.F. Jarvis	Abbott Laboratories, USA
M.J. Kuhar	Emory University, USA
R. Lewis	University of Queensland, Australia
M.J. Marino	Cephalon, Inc., USA
P. McGonigle	PsychoGenics, USA
H. Möhler	University of Zurich, Federal Institute of Technology, Switzerland
A. Schousboe	Danish University of Pharmaceutical Sciences, Denmark
R.D. Speakman	Harvard University Medical School, USA
D.J. Triggie	State University of New York - Buffalo, USA
D. Weinschenker	Emory University, USA
J.M. Witkin	Lilly Corporate Center, USA

Pharmacokinetics & Drug Metabolism

K-I. Inui	Kyoto University Hospital, Japan
D.E. Mager	University at Buffalo, SUNY, USA

Toxicology

K.W. Bock	University of Tübingen, Germany
B.J. Day	National Jewish Medical and Research Center, USA